loader image
Sunday, January 18, 2026
47.6 F
McAllen
- Advertisement -

FDA Approves Daily Pill to Treat Low Libido in Women After Menopause

Health & LifestyleNews
747

Listen to article (english)

Translate to Spanish or other 102 languages!

On December 15, 2025, the U.S. Food and Drug Administration (FDA) approved the medication Addyi (flibanserin) for the treatment of hypoactive sexual desire disorder (HSDD) in postmenopausal women under the age of 65. Image for illustration purposes
On December 15, 2025, the U.S. Food and Drug Administration (FDA) approved the medication Addyi (flibanserin) for the treatment of hypoactive sexual desire disorder (HSDD) in postmenopausal women under the age of 65. Image for illustration purposes

Mega Doctor News

- Advertisement -

Medical News Today

On December 15, 2025, the U.S. Food and Drug Administration (FDA) approved the medication Addyi (flibanserin) for the treatment of hypoactive sexual desire disorder (HSDD) in postmenopausal women under the age of 65.

Addyi was previously approved in 2015 for the treatment of HSDD in premenopausal women. Premenopause or “before” menopause refers to the reproductive time in a cisgender woman’s life when they have regular menstrual cycles.

- Advertisement -

Follow the link below to Medical News Today to read the full story:

https://www.medicalnewstoday.com/articles/fda-approves-daily-pill-treat-low-libido-women-postmenopause-explainer?utm_term=feature&utm_source=Sailthru%20Email&utm_medium=Email&utm_campaign=MNT%20Daily%20News&utm_content=2025-12-19&apid=&rvid=4ba4ec80177cae00eabc43b8bc6648d598c4a356d104663735777e0a0f8b5c9f

Information source: https://www.medicalnewstoday.com

- Advertisement -
- Advertisement -

Latest news

- Advertisement -
Previous article
Heart Association Highlights 2025’s Major Research Findings
Next article
From Patient to Hero: Isaac Garza Delivers 2,089 Smiles This Holiday Season

More Articles

DHR Health Backs Education at 30th Annual VAMOS Golf Tournament

The Valley Alliance of Mentors for Opportunities and Scholarships (VAMOS) will hold a press conference on Wednesday, January 28, 2026, at 10:00 a.m. at the Edinburg Conference Center at Renaissance, located at 118 Paseo Del Prado, Edinburg, TX 78539,  to announce DHR Health as the Presenting Sponsor of the 30th Annual VAMOS Golf Tournament, scheduled for Saturday, March 7, 2026 at Champion Lakes Golf Course in McAllen, Texas. This is the organization’s largest fundraiser and one of the most anticipated charitable sporting events in the region.

Abdominal Muscle Quality Identified as Major Factor in Fall Risk

Artificial intelligence (AI) applied to abdominal imaging can help predict adults at higher risk of falling as early as middle age, a new Mayo Clinic study shows.

Abbott Directs State Agencies to Probe Possible Medicaid Fraud

Governor Greg Abbott sent a letter directing the Texas Health and Human Services (HHS) Office of Inspector General and the Texas Health and Human Services Commission (HHSC) to launch investigations into potential Medicaid fraud in Texas to safeguard taxpayer funds, maintain access for eligible Texans, and ensure efficient, high-quality healthcare delivery.

Algorithm Forecasts Decades‑Long Mortality Outcomes in Prostate Cancer

Prostate cancer is the second-leading cause of cancer death in American men.
- Advertisement -

We feature articles about leading professionals in the medical and healthcare industry in the South Texas area. We are your connection to the medical community!

Pick up a copy of our publication on more than 800 locations Valley-wide.

Contact Us

Office (956) 928-1255

Sales (956) 451-4585

info@tbbmega.com

sales@tbbmega.com

Subscribe

© Mega Doctor News 2025

×